Experts told Law360 that Health and Human Services Secretary Robert F. Kennedy Jr. appears to be avoiding “politically unsavory” issues and focusing on more popular health policies across his hearings this week. Here, Law360 looks at experts' three takeways.
New federal guidance points to regulator flexibility on appropriate alternatives to using animals for testing drug safety.
A smattering of biotech companies have signaled plans to go public in recent days, kicking off what industry insiders expect to be a busy spring and summer for the public markets. Despite a rocky past few weeks for geopolitics, industry insiders are hopeful that 2026's initial public offering market could trigger a steady return to normalcy.